Global Adalimumab Drugs Market Report and Forecast 2024-2032

Global Adalimumab Drugs Market Outlook

The global adalimumab drugs market size is driven by rising emphasis on developing targeted therapies across the globe. The market is expected to grow at a CAGR of 5.1% during the forecast period of 2024-2032.

Global Adalimumab Drugs Market Overview

Adalimumab is a generic name for Humira medicine and its biosimilars. It is a TNF alpha inhibitor used to reduce inflammation and pain, along with skin associated symptoms in chronic autoimmune conditions, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), plaque psoriasis (Ps), Crohn's disease, ankylosing spondylitis, uveitis, ulcerative colitis, and juvenile idiopathic arthritis. The adalimumab drugs market demand is primarily driven by the increasing prevalence of autoimmune diseases.

Rheumatoid arthritis has a prevalence of 40 per 100,000 people  in the United States and Northern European countries. Psoriatic arthritis is estimated to have a prevalence of 0.05 to 0.25%  in the general population whereas the psoriasis affected patients are more likely to develop the condition (6% to 41%). The prevalence rate of ulcerative colitis was estimated to be around 5 million  in 2023.  Lifestyle changes such as elevated stress levels, unhealthy dietary habits and environmental factors have all contributed to the higher incidence.

Biosimilars Expected to Lead the Adalimumab Drugs Market Share

Owing to the easy availability and high efficacy, adalimumab drugs has garnered wide popularity in recent years. With rising technical advancements in medical technology and a heightened focus on personalised medicines, the production, and regulatory approvals for biosimilars has increased.

In July 2023, Boehringer Ingelheim’s interchangeable adalimumab biosimilar, called Cyltzo  received FDA approval and was made commercially available in the United States market. The approval was based on the promising results showcased in Phase III randomized VOLTAIRE-X comparative clinical trial. The increasing approvals to offer improved and affordable solutions to the patients is anticipated to be a major factor boosting the adalimumab drugs market growth in the forecast period.

In March 2023, Sandoz , a pioneer in generic pharmaceuticals and biosimilars received FDA approval for citrate-free high-concentration formulation (HCF) of its biosimilar Hyrimoz® (adalimumab-adaz) injection. The approval was based on Phase I pharmacokinetics (PK) study that compared adalimumab 50 mg/mL to the citrate-free 100 mg/mL. Hyrimoz® marks the first launch of a Sandoz biosimilar in the United States market.

Collaborative Efforts with Online Pharmacies to Make the Drug Available at an Affordable Price

To offer better accessibility and affordability of drugs to patients, there is a rising focus on making biosimilars available in online pharmacies. In June 2023, Coherus Biosciences  partnered with Mark Cuban Cost Plus Drug Company’s online pharmacy chain to offer adalimumab’s biosimilar, YUSIMRY (adalimumab-aqvh) at a pocket-friendly price. YUSIMRY is enabled with art autoinjector presentation and integrates the non-stinging, citrate free formulation and a 29-gauge needle by Coherus Biosciences. Understanding the rising popularity and preference of at-home services, this partnership is expected to open a new realm of convenience for patients, fuelling a rise in the adalimumab drugs market size significantly.

Global Adalimumab Drugs Market Segmentation

Market Breakup by Indication

• Rheumatoid Arthritis

• Psoriatic Arthritis

• Ankylosing Spondylitis

• Chronic Plaque Psoriasis

• Crohn's Disease

• Ulcerative Colitis

• Others

Market Breakup by Type

• Biologics

• Biosimilars

Market Breakup by Route of Administration

• Oral

• Parenteral

• Others

Market Breakup by Age Group

• Pediatric

• Adult

• Geriatric

Market Breakup by Distribution Channel

• Hospitals

• Specialty Clinics

• Homecare

• Others

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Global Adalimumab Drugs Market Regional Analysis

North America, particularly the United States, is projected to lead the global market. The market size can be accredited to the presence of prominent pharmaceutical companies, continuously working on producing biosimilars along with proactive regulatory authorities such as the United States FDA for maintaining the quality of the drugs.

Owing to a substantial portion of the geriatric population in the region, Europe turns out to be another key market. The older population is more susceptible to develop diseases such as arthritis, hence the government is taking multiple initiatives to promote effective treatment methods. The presence of influential academic and research institutions along with a well-structured research infrastructure also fuels market growth.

The Asia Pacific adalimumab drugs market value is poised to witness ample growth, accredited to rising improvements in the region’s healthcare infrastructure. Emerging economies such as India and South Korea are major centres of foreign investments. In addition, there is a trend of growing collaborations between private and public institutions to offer the best treatment outcomes to patients.

Global Adalimumab Drugs Market: Competitor Landscape

In January 2023, Amgen  made AMJEVITA™ (their biosimilar to Humira) available in their United States market. The biosimilar was available at a price 55% lower than the standard Humira price, facilitating a better access to a wider section of the patients. In addition, it was available in prefilled syringe as well as autoinjector presentations to support dosing based on approved indications. This indicates a common market trend involving a greater number of companies working to develop biosimilars.

The key features of the adalimumab drugs market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• F. Hoffmann-La Roche Ltd.

• Mylan N.V.

• Teva Pharmaceutical Industries Ltd.

• Sanofi

• GlaxoSmithKline plc

• Novartis AG

• Pfizer Inc. (US)

• Biogen

• Fresenius Kabi AG

• Zydus Cadila

• Boehringer Ingelheim International GmbH

• Amgen Inc.

• AbbVie Inc.

• Abbott

• CELLTRION INC.

• Samsung Bioepis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

Adalimumab Drugs Market Report Snapshots

Adalimumab Drugs Market Size

Adalimumab Drugs Market Analysis

Adalimumab Drugs Companies